The reduction of Baseline serotonin 2A receptors in mild cognitive impairment is stable at two-year follow-up

Journal of Alzheimer's Disease

Volumn 23, Issue 3, 2011, Pages 453-459

  Marner, Lisbeth ^a   Knudsen, Gitte M ^a   Madsen, Karine ^a   Holm, Søren ^a   Baaré, William ^a,b   Hasselbalch, Steen G ^a  

^a Rigshospitalet   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Alzheimer's disease; brain; humans; neurodegenerative disease; PET; positronemission tomography

Indexed keywords

ALTANSERIN; ALTANSERIN F18; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NEOCORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; RECEPTOR BINDING; TEMPORAL CORTEX;

EID: 79951904150     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100903     Document Type: Article

References (40)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
2. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58, 397-405. (Pubitemid 32217456)
3. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281, 1401-1406. (Pubitemid 29190218)
4. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, GalaskoD, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl JMed 352, 2379-2388. (Pubitemid 40958434)
5. Raschetti R, Albanese E, Vanacore N, Maggini M (2007) Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4, e338.
6. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300, 2253-2262.
7. Aletrino MA,Vogels OJ, van Domburg PH, Ten Donkelaar HJ (1992) Cell loss in the nucleus raphes dorsalis in Alzheimer's disease. Neurobiol Aging 13, 461-468.
8. Halliday GM, McCann HL, Pamphlett R, Brooks WS, Creasey H, McCusker E, Cotton RG, Broe GA, Harper CG (1992) Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. Acta Neuropathol 84, 638-650.
9. Tejani-Butt SM, Yang J, Pawlyk AC (1995) Altered serotonin transporter sites in Alzheimer's disease raphe and hippocampus. Neuroreport 6, 1207-1210.
10. Hendricksen M, Thomas AJ, Ferrier IN, Ince P, O'Brien JT (2004) Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am J Psychiatry 161, 1096-1102. (Pubitemid 38735997)
11. Ouchi Y, Yoshikawa E, Futatsubashi M, Yagi S, Ueki T, Nakamura K (2009) Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. J Nucl Med 50, 1260-1266.
12. Marner L, Frokjaer VG, Kalbitzer J, Lehel S, Madsen K, BaaréW, Knudsen GM, Hasselbalch SG (2010) Loss of sero- tonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study. Neurobiol Aging, in press.
13. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi- Jadid K, Cole GM, SatyamurthyN, Cummings JL, SmallGW, Phelps ME (2006) Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A 103, 702-707. (Pubitemid 43153089)
14. Lanctot KL, Hussey DF, Herrmann N, Black SE, Rusjan PM, Wilson AA, Houle S, Kozloff N, Verhoeff NP, Kapur S (2007) A positron emission tomography study of 5-hydroxytryptamine- 1A receptors in Alzheimer disease. Am J Geriatr Psychiatry 15, 888-898.
15. Truchot L, Costes N, Zimmer L, Laurent B, Le BD, Thomas-Anterion C, Mercier B, Hermier M, Vighetto A, Krolak-Salmon P (2008) A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease. Neuroimage 40, 1251-1256.
16. Blin J, Baron JC, Dubois B, Crouzel C, Fiorelli M, Ttar-Levy D, Pillon B, Fournier D, Vidailhet M, Agid Y (1993) Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. Brain 116, 497-510. (Pubitemid 23203635)
17. Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR, Mulsant BH, Ben-Eliezer D, Lopresti B, DeKosky ST, Reynolds CF III (1999) PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry 156, 1871-1878.
18. Berg KA, Harvey JA, Spampinato U, ClarkeWP (2005) Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends Pharmacol Sci 26, 625-630. (Pubitemid 41636307)
19. Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, Waldemar G, Knudsen GM (2008) Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging 29, 1830-1838.
20. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A (2004) MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63, 2332-2340. (Pubitemid 40024346)
21. Marner L, Knudsen GM, Haugbol S, Holm S, Baare W, Hasselbalch SG (2009) Longitudinal assessment of cerebral 5-HT(2A) receptors in healthy elderly volunteers: an [(18)F]- altanserin PET study. Eur J Nucl Med Mol Imaging 36, 287-293.
22. Hogh P, Waldemar G, Knudsen GM, Bruhn P, Mortensen H, Wildschiodtz G, Bech RA, Juhler M, Paulson OB (1999) A multidisciplinary memory clinic in a neurological setting: diagnostic evaluation of 400 consecutive patients. Eur J Neurol 6, 279-288. (Pubitemid 29250986)
23. Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412-2414. (Pubitemid 23346995)
24. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
25. Pinborg LH, Adams KH, Svarer C, Holm S, Hasselbalch SG, Haugbol S, Madsen J, Knudsen GM (2003) Quantification of 5-HT2A receptors in the human brain using [18F]altanserin- PET and the bolus/infusion approach. J Cereb Blood Flow Metab 23, 985-996. (Pubitemid 36959405)
26. Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbol S, Madsen K, Frokjaer V, Martiny L, Paulson OB, KnudsenGM(2004)Adatabase of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage 21, 1105-1113. (Pubitemid 38314973)
27. Woods RP, Cherry SR, Mazziotta JC (1992) Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16, 620-633.
28. Müller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ (1992) Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 12, 571-583.
29. Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L, Alfano B, Brunetti A, Baron JC, SalvatoreM(2004) Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med 45, 192-201. (Pubitemid 47618636)
30. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG, Holm S, Paulson OB, Knudsen GM (2005) MR-based automatic delineation of volumes of interest in human brainPETimages using probability maps. Neuroimage 24, 969-979. (Pubitemid 40164499)
31. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E (2001) Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49, 175-184. (Pubitemid 32178426)
32. Marutle A,Warpman U, Bogdanovic N, Lannfelt L, Nordberg A (1999) Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation. J Neurochem 72, 1161-1169. (Pubitemid 29085032)
33. Sabri O, Kendziorra K, Wolf H, Gertz HJ, Brust P (2008) Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 35, S30-S45.
34. Ellis JR, Villemagne VL, Nathan PJ, Mulligan RS, Gong SJ, Chan JG, Sachinidis J, O'Keefe GJ, Pathmaraj K,Wesnes KA, Savage G, Rowe CC (2008) Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. Neurobiol Learn Mem 90, 404-412.
35. Mitsis EM, Reech KM, Bois F, Tamagnan GD, Macavoy MG, Seibyl JP, Staley JK, van Dyck CH (2009) 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment. J Nucl Med 50, 1455-1463.
36. Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, Hedden T, Becker JA, Rentz DM, Selkoe DJ, JohnsonKA(2010) Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med 12, 27-43.
37. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66, 1469-1475.
38. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844. (Pubitemid 350033975)
39. Jack CR Jr., Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365.
40. Holm P, Ettrup A, Klein AB, Santini MA, El-Sayed M, Elvang AB, Stensbol TB, Mikkelsen JD, Knudsen GM, Aznar S (2010) Plaque deposition dependent decrease in 5-HT2A serotonin receptor in AbetaPPswe/PS1dE9 amyloid overexpressing mice. J Alzheimers Dis 20, 1201-1213.